ARS Pharmaceuticals (SPRY) Capital Expenditures (2020 - 2025)

ARS Pharmaceuticals has reported Capital Expenditures for 6 years, with the latest figure at -$5.5 million in Q3 2025.

• Quarterly Capital Expenditures fell 2215.33% year-over-year to -$5.5 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $248000.0 (down 56.57% YoY) and the FY2025 annual result came in at $339000.0, down 39.79% from the prior year.
• Capital Expenditures eased to -$5.5 million in Q3 2025 per SPRY's latest filing, from $5.8 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $5.8 million in Q2 2025 and troughed at -$5.5 million in Q3 2025.
• A 5-year average of $70888.9 and a median of $83500.0 in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2021 and 2025: Capital Expenditures surged 13900.0% in 2021, then sank 2215.33% in 2025.
• Over 5 years, Capital Expenditures stood at -$822000.0 in 2021, then jumped by 115.33% to $126000.0 in 2022, then plunged by 33.33% to $84000.0 in 2023, then soared by 259.52% to $302000.0 in 2024, then tumbled by 1928.15% to -$5.5 million in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$5.5 million, $5.8 million, and $91000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.